Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microvision (MVIS) -- Ignore unavailable to you. Want to Upgrade?

To: kili who wrote (2928)	6/16/1999 8:44:00 AM
From: Ronald Kronemann	Read Replies (1) \| Respond to of 7721

News about LOI with Zeiss (yesterday there was a rumor on the Yahoo Board). Lets hope it will scare all shorts to death. Ronald -------------------------------------- Wednesday June 16, 6:00 am Eastern Time Company Press Release SOURCE: Microvision, Inc. Microvision Teams with Zeiss to Develop Ophthalmic Products Companies Sign Letter of Intent to Commercialize VRD-based Medical Products BOTHELL, Wash., June 16 /PRNewswire/ -- Microvision, Inc. (Nasdaq: MVIS - news, MVISW - news) today announced that it has entered into a letter of intent with Carl Zeiss, Inc., a world leader in precision optics, to jointly develop a range of ophthalmic, visualization and imaging devices that will utilize Microvision's VRD technology across a broad range of medical instruments. Under the terms of the agreement, the companies have agreed to pursue opportunities to develop functional experimental devices, complete testing and validation including clinical studies, and ensure effective collaboration through final product development and the development of marketing and sales strategies. For competitive reasons the companies have not yet provided specific details of the products under consideration, but said that they plan to build and test market several demonstration systems based on Microvision's VRD technology during the coming months. ''This marks the beginning of a truly exciting partnership with one of the world's long standing leaders in high quality optical instrumentation. The Zeiss name is synonymous with unsurpassed quality in a variety of medical and commercial product categories,'' said Rick Rutkowski, Microvision President and CEO. ''Zeiss' optics design and manufacturing capabilities and their product presence make an excellent fit to leverage Microvision's enabling technology. Together we see a significant market for medical products enabled by VRD technology and we stand ready to provide truly innovative and powerful products for these markets. We're looking forward to sharing more information as the relationship develops and as we get closer to products.'' About Microvision Headquartered in Bothell, Wash., Microvision, Inc. (Nasdaq: MVIS MVISW) is the developer of the patented Virtual Retinal Display(TM) (VRD(TM)) technology that uses a rapidly scanned beam of light to project images on the eye's retina, allowing the viewer to see large, full-motion images without the need for a conventional display screen. Microvision's objective is to be a leading provider of personal display products and imaging technology in a broad range of military, medical, industrial, professional and consumer applications. The company was founded in 1993. Additional information can be found at the company's web site at mvis.com . About Carl Zeiss Carl Zeiss sells and services a broad line of optical, scientific and industrial instruments worldwide and has a 150-year heritage of developing and manufacturing high quality optical systems. Carl Zeiss has an international network of dedicated and direct sales representatives and gives its customers the best possible service for its instruments through a network of factory trained personnel. Additional information about the range of Zeiss products can be found at the company's web site at zeiss.com . Forward-Looking Statement The information set forth in this release includes ''forward-looking statements'' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created by those sections. Certain factors that realistically could cause results to differ materially from those projected in the company's forward-looking statements are set forth in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. SOURCE: Microvision, Inc.